INmune Bio receives FDA alignment to advance XPro1595 to registrational study in Alzheimer's

Inmune Bio, Inc.

FDA End-of-Phase 2 meeting yielded alignment to proceed with registrational study in biomarker-enriched early Alzheimer's patients.
Phase 2 MINDFuL trial results and FDA feedback to be detailed in a webinar on Feb 27, 2026 at 9:30 AM ET.
Company will seek a global partnership to maximize XPro1595's clinical and commercial potential.
Key opinion leaders Dr. Michael Woodward and Dr. Sharon Cohen to present MINDFuL trial data and discuss pathway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.